On warfarin use in kidney disease: A therapeutic window of opportunity?

American Journal of Kidney Diseases

Volumn 56, Issue 5, 2010, Pages 805-808

  Nolin, Thomas D ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; DRUG CLEARANCE; DRUG EXPOSURE; DRUG METABOLISM; EDITORIAL; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FAILURE; PHARMACOGENETICS; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; VASCULAR ACCESS; BLOOD; COMPLICATION; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR; THROMBOPHILIA;

ANTICOAGULANTS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; RISK FACTORS; THROMBOPHILIA; WARFARIN;

EID: 77958469845     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.09.007     Document Type: Editorial

References (22)

1. C.M. Kunin A guide to use of antibiotics in patients with renal disease A table of recommended doses and factors governing serum levels Ann Intern Med 67 1 1967 151 158
2. T.D. Nolin, R.F. Frye, and G.R. Matzke Hepatic drug metabolism and transport in patients with kidney disease Am J Kidney Dis 42 5 2003 906 925
3. B.L. Hug, D.J. Witkowski, and C.M. Sox Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those excreted by the kidney Kidney Int 76 11 2009 1192 1198
4. N.A. Limdi, M.A. Limdi, and L. Cavallari Warfarin dosing in patients with impaired kidney function Am J Kidney Dis 56 5 2010 823 831
5. M.J. Kim, S.M. Huang, U.A. Meyer, A. Rahman, and L.J. Lesko A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity J Clin Pharmacol 49 2 2009 138 146
6. Coumadin® (warfarin) prescribing information January 2010 Bristol-Myers Squibb Co Princeton, NJ http://packageinserts.bms.com/pi/pi- coumadin.pdf Accessed September 20, 2010
7. A.K. Hamberg, M. Wadelius, and J.D. Lindh A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age Clin Pharmacol Ther 87 6 2010 727 734
8. T.E. Klein, R.B. Altman, and N. Eriksson Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 8 2009 753 764
9. L.H. Cavallari, T.Y. Langaee, and K.M. Momary Genetic and clinical predictors of warfarin dose requirements in African Americans Clin Pharmacol Ther 87 4 2010 459 464
10. P. Lenzini, M. Wadelius, and S. Kimmel Integration of genetic, clinical, and INR data to refine warfarin dosing Clin Pharmacol Ther 87 5 2010 572 578
11. D.S. Budnitz, N. Shehab, S.R. Kegler, and C.L. Richards Medication use leading to emergency department visits for adverse drug events in older adults Ann Intern Med 147 11 2007 755 765
12. C.L. Aquilante, T.Y. Langaee, and L.M. Lopez Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements Clin Pharmacol Ther 79 4 2006 291 302
13. B.F. Gage, C. Eby, and J.A. Johnson Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin Clin Pharmacol Ther 84 3 2008 326 331
14. K.E. Chan, J.M. Lazarus, R. Thadhani, and R.M. Hakim Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients J Am Soc Nephrol 20 10 2009 872 881
15. W.M. Bennett Should dialysis patients ever receive warfarin and for what reasons? Clin J Am Soc Nephrol 1 6 2006 1357 1359
16. M.M. Sood, P. Komenda, A.R. Sood, C. Rigatto, and J. Bueti The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest 136 4 2009 1128 1133
17. G. Finazzi, and G. Mingardi Oral anticoagulant therapy in hemodialysis patients: do the benefits outweigh the risks? Intern Emerg Med 4 5 2009 375 380
18. K.E. Chan, J.M. Lazarus, R. Thadhani, and R.M. Hakim Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation J Am Soc Nephrol 20 10 2009 2223 2233
19. N.A. Limdi, T.M. Beasley, and M.F. Baird Kidney function influences warfarin responsiveness and hemorrhagic complications J Am Soc Nephrol 20 4 2009 912 921
20. A.W. Dreisbach, S. Japa, and A.B. Gebrekal Cytochrome P4502C9 activity in end-stage renal disease Clin Pharmacol Ther 73 5 2003 475 477
21. Y. Zhang, L. Zhang, and S. Abraham Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications Clin Pharmacol Ther 85 3 2009 305 311
22. S.M. Huang, R. Temple, S. Xiao, L. Zhang, and L.J. Lesko When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective Clin Pharmacol Ther 86 5 2009 475 479